Corrigendum to: Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Login or register to view PDF.
Creative Commons Licence
 
Received date
29 July 2020
Accepted date
29 July 2020
Citation
Interventional Cardiology Review 2020;15:e12.
DOI
https://doi.org/10.15420/icr.2020.22
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

In the article by Taramasso et al. entitled Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies (Interventional Cardiology Review 2017;12(1):51–5. https://doi.org/10.15420/icr.2017:3:2), the following correction should be made.

The authors’ conflicts of interest were omitted at the time of publication. They should read as follows:

Maurizio Taramasso is a consultant for Abbott Vascular, Boston Scientific and 4tech; received personal fees from Edwards Lifesciences, Mitraltech, CoreMedic and Swissvortex; and is a shareholder of 4Tech.

Fabian Nietlispach serves a consultant for Edwards Lifesciences, Abbott, Medtronic and St Jude Medical.

Michel Zuber is a consultant for Abbott and Edwards Lifesciences.

Francesco Maisano discloses grant and/or research support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT and Terumo; consulting fees and honoraria from Abbott, Medtronic, Edwards Lifesciences, Swissvortex, Perifect, Xeltis, Transseptal Solutions, Cardiovalve (Mitraltech) and Magenta; royalty income/IP rights from Edwards Lifesciences; and is a shareholder of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech and Perifect.

All other authors have no conflicts of interest to declare.

The authors apologise for this error.